Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Amatuximab |
| Synonyms | |
| Therapy Description |
Amatuximab is a chimeric IgG anti-mesothelin monoclonal antibody, which induces an immune response against cells overexpressing mesothelin (PMID: 25502863, PMID: 30333914). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Amatuximab | MORAb-009 | MSLN Antibody 13 | Amatuximab is a chimeric IgG anti-mesothelin monoclonal antibody, which induces an immune response against cells overexpressing mesothelin (PMID: 25502863, PMID: 30333914). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02357147 | Phase II | Cisplatin + Pemetrexed Disodium Amatuximab | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS) | Terminated | USA | ITA | GBR | FRA | DEU | AUS | 0 |